CN106279057A - Ataluren的新合成方法 - Google Patents
Ataluren的新合成方法 Download PDFInfo
- Publication number
- CN106279057A CN106279057A CN201610674890.3A CN201610674890A CN106279057A CN 106279057 A CN106279057 A CN 106279057A CN 201610674890 A CN201610674890 A CN 201610674890A CN 106279057 A CN106279057 A CN 106279057A
- Authority
- CN
- China
- Prior art keywords
- ataluren
- compound
- novel synthesis
- reducing agent
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OOUGLTULBSNHNF-UHFFFAOYSA-N 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(ON=2)C=2C(=CC=CC=2)F)=C1 OOUGLTULBSNHNF-UHFFFAOYSA-N 0.000 title claims abstract description 24
- 229960003995 ataluren Drugs 0.000 title claims abstract description 23
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 16
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 16
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000006243 chemical reaction Methods 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 6
- -1 (4 nitrobenzophenone) phosphate ester Chemical class 0.000 claims abstract description 5
- NBBQQQJUOYRZCA-UHFFFAOYSA-N diethoxymethylsilane Chemical compound CCOC([SiH3])OCC NBBQQQJUOYRZCA-UHFFFAOYSA-N 0.000 claims abstract description 5
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000003197 catalytic effect Effects 0.000 claims abstract description 3
- 229940125782 compound 2 Drugs 0.000 claims abstract description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 229940126214 compound 3 Drugs 0.000 claims description 4
- 150000004820 halides Chemical class 0.000 claims description 4
- DRUIESSIVFYOMK-UHFFFAOYSA-N Trichloroacetonitrile Chemical compound ClC(Cl)(Cl)C#N DRUIESSIVFYOMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 238000010189 synthetic method Methods 0.000 claims description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 claims 2
- GCSVCUMDOQKEMT-UHFFFAOYSA-N butan-1-amine;hydrofluoride Chemical compound [H+].[F-].CCCCN GCSVCUMDOQKEMT-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000007613 environmental effect Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 201000003883 Cystic fibrosis Diseases 0.000 description 5
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 4
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 102000001039 Dystrophin Human genes 0.000 description 3
- 108010069091 Dystrophin Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000035126 Facies Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 210000001766 X chromosome Anatomy 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- NSTREUWFTAOOKS-UHFFFAOYSA-N 2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1F NSTREUWFTAOOKS-UHFFFAOYSA-N 0.000 description 1
- GYLKKXHEIIFTJH-UHFFFAOYSA-N 3-cyanobenzoic acid Chemical compound OC(=O)C1=CC=CC(C#N)=C1 GYLKKXHEIIFTJH-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种Ataluren的新合成方法。该方法包括以下步骤：步骤1，化合物2在碱性条件下和盐酸羟胺反应得到中间体3；步骤2，在还原剂二乙氧基甲基硅烷和双(4‑硝基苯基)磷酸酯存在下，催化量的三苯基膦和等当量的四氯化碳和化合物4反应得到目标化合物Ataluren(1)。该方法原料易得，合成步骤简短，环境友好，后处理方便，具有良好的工业生产价值。
Description
技术领域
本发明涉及用于治疗杜氏肌营养不良症和囊性纤维化症的药物Ataluren的新合成方法。
背景技术
杜氏肌营养不良症(DMD)是一种X染色体隐性遗传疾病，多发于男性。平均每3600个男婴中就有一例。其病因为位于X染色体上肌营养不良蛋白(dystrophin)的遗传基因发生突变，而肌营养不良蛋白是稳定肌肉组织细胞膜的一个重要部份。它最重要的功能是维持肌肉细胞的稳定性，使肌肉在收缩的过程中不会受到破坏，由于杜氏肌营养不良症患者缺少此种蛋白，其肌肉细胞从其出生以来便不断受到破坏和萎缩。囊性纤维化症(cysticfibrosis)是一种染色体隐形遗传疾病，主要影响肺部和消化系统，多见于欧罗巴人种，表现症状为呼吸困难、咳嗽时会伴随十分粘稠的液体、粪便脂肪含量很高。其病因为用于合成囊性纤维化跨膜传导调节因子(CFTR)蛋白的基因发生突变。CFTR与汗液、消化液、粘液的分泌有密切关系。当CFTR失去功能时分泌液就会变浓。直到上世纪末，这两类疾病患者的寿命都很短，严重影响生活质量。
虽然根治杜氏肌营养不良症和囊性纤维化症的药物尚未被发现，但对于控制病情及改善患者生活质量的药物不断地被研发。
Ataluren原名是PTC124，化学名称为3-(5-(2-氟苯基)-[1，2，4]-噁二唑-3-基)苯甲酸。是PTC公司(PTC Therapeutics)开发的一类用于治疗无义突变导致的杜氏肌营养不良症和囊肿性纤维化症的药物。
目前已经有众多的合成Ataluren的方法，如中国专利CN 101535284A等。还包括期刊Drug of the future，2008，33(9)，733；New J.Chem.，2014，38，3062-3070；Adv.Synth.Catal.，2014，356，3074-3082等。这些公开的专利或文献采用的合成方法主要存在以下缺点：
1.反应路线普遍比较长，总收率偏低；
2.某些合成过程中会产生二氧化硫、氯化氢等气体，环境污染严重；
3.噁二唑环构建过程需要使用到脱水剂，制备成本较高，不适合工业化生产。
发明内容
本发明的目的是提供一种Ataluren的新合成方法，该方法合成路线短，环境友好，产物收率高，适合工业化生产。
为了达到上述目的，本发明提供了一种Ataluren的新合成方法，具体合成路线如下式所示：
步骤1，化合物2在碱性条件下和盐酸羟胺回流反应，生产中间体3。
步骤2，在还原剂存在下，化合物4通过催化量的三苯基膦和等当量的卤化试剂活化，四丁基氟化铵催化下和化合物3反应，得到目标化合物Ataluren。
上述Ataluren的新合成方法，其中，步骤2过程中的还原剂为二乙氧基甲基硅烷和双(对硝基苯基)磷酸酯。
上述Ataluren的新合成方法，其中，步骤2过程中的卤化试剂选自四氯化碳，四溴化碳，三氯乙腈等，优选四氯化碳。
上述Ataluren的新合成方法，其中，步骤2过程中的催化剂为四丁基氟化铵。
上述Ataluren的新合成方法，其中，步骤2过程中反应所采用的温度为30-150℃，优选120℃。
具体实施方式
以下将通过实施例进一步描述本发明，但是，这些描述仅用于说明本发明，不是对本发明的限制。
一、化合物3的合成
实施例1
将3-氰基苯甲酸(2，147g，1mol)，盐酸羟胺(695g，10mol)和200mL乙醇混合。缓慢投入碳酸钾(1380g，10mol)，90℃油浴加热回流反应。薄层层析(TLC)追踪反应直至3-氰基苯甲酸耗尽。待反应液冷却后加水和乙酸乙酯，分液收集有机相，有机相加入适量无水硫酸钠干燥。减压浓缩得到白色固体化合物3，163.8g，收率91％。
二、Ataluren的合成
实施例2
往反应器中加入邻氟苯甲酸(4，140g，1mol)，化合物3(180g，1mol)，三苯基膦(52.4g，0.2mol)四氯化碳(152g，1mol)，二乙氧基甲基硅烷(202.6g，1.2mol)，双(对硝基苯基)磷酸酯(17.1g，0.05mol)，甲苯500mL。120℃油浴加热冷凝回流反应24小时。待反应液冷却后，用乙酸乙酯萃取，加入无水硫酸钠干燥，减压浓缩蒸干，柱层析得目标化合物Ataluren(1，184.6g)，白色固体，收率65％。
Claims (6)
1.一种Ataluren的新合成方法，其特征在于该方法包含以下具体步骤：
步骤1，化合物2在碱性条件下和盐酸羟胺反应得到化合物3；
步骤2，在还原剂存在下，化合物4通过催化量的三苯基膦和等当量的卤化试剂活化，四丁基氟化铵催化下和化合物3反应，得到目标化合物Ataluren。
2.如权利要求1所述的Ataluren的新合成方法，其特征在于，步骤2过程中的还原剂为二乙氧基甲基硅烷和双(对硝基苯基)磷酸酯。
3.如权利要求2所述，还原剂二乙氧基甲基硅烷和双(对硝基苯基)磷酸酯的摩尔比为1.2∶0.05。
4.如权利要求1所述的Ataluren的新合成方法，其特征在于，在步骤2的卤化试剂选自四氯化碳，四溴化碳，三氯乙腈等，优选四氯化碳。
5.如权利要求1所述的Ataluren的新合成方法，其特征在于，在步骤2过程中的催化剂为四丁基氟化铵。
6.如权利要求1所述的Ataluren的合成新方法，其中步骤2过程中反应所采用的温度为30-150℃，优选120℃。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610674890.3A CN106279057B (zh) | 2016-08-15 | 2016-08-15 | Ataluren的合成方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610674890.3A CN106279057B (zh) | 2016-08-15 | 2016-08-15 | Ataluren的合成方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106279057A true CN106279057A (zh) | 2017-01-04 |
| CN106279057B CN106279057B (zh) | 2022-04-15 |
Family
ID=57679895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610674890.3A Active CN106279057B (zh) | 2016-08-15 | 2016-08-15 | Ataluren的合成方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106279057B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111675672A (zh) * | 2020-05-12 | 2020-09-18 | 石家庄市度智医药科技有限公司 | 一种制备阿塔鲁伦的方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101970420A (zh) * | 2007-10-04 | 2011-02-09 | 默克雪兰诺有限公司 | 噁二唑衍生物 |
| CN102076670A (zh) * | 2008-06-24 | 2011-05-25 | Irm责任有限公司 | 调节g蛋白偶联受体的化合物和方法 |
| CN104056278A (zh) * | 2003-04-11 | 2014-09-24 | Ptc治疗公司 | 1,2,4-噁二唑苯甲酸化合物 |
| WO2016073545A1 (en) * | 2014-11-06 | 2016-05-12 | Concert Pharmaceuticals, Inc. | Phenyloxadiazole benzoic acids |
| US20170362192A1 (en) * | 2016-06-20 | 2017-12-21 | Scinopharm Taiwan, Ltd. | Process for preparing ataluren and its intermediates |
-
2016
- 2016-08-15 CN CN201610674890.3A patent/CN106279057B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104056278A (zh) * | 2003-04-11 | 2014-09-24 | Ptc治疗公司 | 1,2,4-噁二唑苯甲酸化合物 |
| CN101970420A (zh) * | 2007-10-04 | 2011-02-09 | 默克雪兰诺有限公司 | 噁二唑衍生物 |
| CN102076670A (zh) * | 2008-06-24 | 2011-05-25 | Irm责任有限公司 | 调节g蛋白偶联受体的化合物和方法 |
| WO2016073545A1 (en) * | 2014-11-06 | 2016-05-12 | Concert Pharmaceuticals, Inc. | Phenyloxadiazole benzoic acids |
| US20170362192A1 (en) * | 2016-06-20 | 2017-12-21 | Scinopharm Taiwan, Ltd. | Process for preparing ataluren and its intermediates |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111675672A (zh) * | 2020-05-12 | 2020-09-18 | 石家庄市度智医药科技有限公司 | 一种制备阿塔鲁伦的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106279057B (zh) | 2022-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rojas et al. | Synthesis and inhibitory activity of dimethylamino-chalcone derivatives on the induction of nitric oxide synthase | |
| García-Álvarez et al. | Ibuprofenamide: a convenient method of synthesis by catalytic hydration of 2-(4-isobutylphenyl) propionitrile in pure aqueous medium | |
| CN102108070A (zh) | 5-氨基苯并呋喃-2-甲酸酯及其中间体的制备方法 | |
| CN106279057A (zh) | Ataluren的新合成方法 | |
| CN105461704A (zh) | 一种依匹哌唑的制备方法 | |
| CN106543034A (zh) | 一种合成7‑甲氧基萘乙腈的方法 | |
| CN103086907B (zh) | 一种醋氯芬酸的制备方法 | |
| CN113816919B (zh) | 一种氯唑沙宗的制备方法 | |
| Zhou et al. | Reactions of 2-methylthiazolines and N-methyl cyclic ketene-N, S-acetals with acid chlorides | |
| CN113816920B (zh) | 一种氯唑沙宗的合成方法 | |
| CN109574818A (zh) | 一种多取代茚酮衍生物及其制备方法 | |
| CN106866425A (zh) | 一种溴代芳香胺和α‑溴代芳香酮的绿色合成方法 | |
| CN108358865A (zh) | 一种新型的多取代噻唑类化合物的制备方法 | |
| CN104974059B (zh) | 一种利伐沙班中间体及其制备方法 | |
| CN104592086B (zh) | 一种通过铜盐催化制备吲哚类化合物的方法 | |
| CN102627595A (zh) | 一种制备格隆溴铵的方法 | |
| CN104418793A (zh) | 抗阿茨海默症药物Lu-AE-58054的制备方法 | |
| CN107778257A (zh) | 一种哌嗪衍生物的合成方法 | |
| CN106588909A (zh) | 一种喹啉类衍生物的制备及其在抗炎中的应用 | |
| CN106045827B (zh) | 一种芳基丙酮类化合物的制备方法 | |
| Ghosh et al. | Reactivity of conformationally constrained bispropargyl sulfones: complete preference for 6π-electrocyclization process | |
| Chen et al. | Air-triggered, catalyst-free decarboxylative oxysulfonylation of arylpropiolic acids with sodium sulfinates | |
| CN105294532B (zh) | 一种l‑羟基脯氨酸的制备方法 | |
| WO2021134143A1 (zh) | 一种制备二氮嗪的方法 | |
| CN107954934A (zh) | 一种氟虫腈中间体的合成方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190805 Address after: 510530 Room 205, 2nd Floor, Block B8, 11 Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province Applicant after: Guangzhou Ming Pharmaceutical Technology Co.,Ltd. Address before: 523808 Guangdong city of Dongguan Province Academic Exchange Center of the Songshan Lake high tech Industrial Development Zone A floor room 304 Applicant before: DONGGUAN MINGRI PHARMACEUTICAL CO.,LTD. |
|
| DD01 | Delivery of document by public notice |
Addressee: Ye Qizhuang Document name: Notification of Passing Examination on Formalities |
|
| DD01 | Delivery of document by public notice | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Synthesis of Ataluren Effective date of registration: 20220914 Granted publication date: 20220415 Pledgee: Bank of China Limited Guangzhou Development Zone Branch Pledgor: Guangzhou Ming Pharmaceutical Technology Co.,Ltd. Registration number: Y2022980015134 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231023 Granted publication date: 20220415 Pledgee: Bank of China Limited Guangzhou Development Zone Branch Pledgor: Guangzhou Ming Pharmaceutical Technology Co.,Ltd. Registration number: Y2022980015134 |